[HTML][HTML] Pre-clinical models of metastasis in pancreatic cancer
M Miquel, S Zhang, C Pilarsky - Frontiers in cell and developmental …, 2021 - frontiersin.org
Pancreatic ductal adenocarcinoma (PDAC) is a hostile solid malignancy coupled with an
extremely high mortality rate. Metastatic disease is already found in most patients at the time …
extremely high mortality rate. Metastatic disease is already found in most patients at the time …
Symptom management in pancreatic cancer
KG Lee, V Roy, M Laszlo, KM Atkins, KJ Lin… - … treatment options in …, 2021 - Springer
Opinion statement Despite extensive research that has identified new risk factors, genetic
mutations, and therapeutic options, pancreatic ductal adenocarcinoma continues to be a …
mutations, and therapeutic options, pancreatic ductal adenocarcinoma continues to be a …
[HTML][HTML] Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview
Pancreatic cancer (PC) remains one of the most lethal and incurable forms of cancer and
has a poor prognosis. One of the significant therapeutic challenges in PC is multidrug …
has a poor prognosis. One of the significant therapeutic challenges in PC is multidrug …
[HTML][HTML] Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies
MY Han, EH Borazanci - Frontiers in Oncology, 2023 - frontiersin.org
Malignant ascites is the accumulation of fluid in the peritoneum as a result of advanced
cancer and often signifies the terminal phase of the disease. Management of malignant …
cancer and often signifies the terminal phase of the disease. Management of malignant …
[HTML][HTML] Establishment of patient-derived organoids using ascitic or pleural fluid from cancer patients
Purpose Patient-derived tumor cells can be a powerful resource for studying
pathophysiological mechanisms and developing robust strategies for precision medicine …
pathophysiological mechanisms and developing robust strategies for precision medicine …
Autotaxin in ascites promotes peritoneal dissemination in pancreatic cancer
N Jinno, M Yoshida, K Hayashi, I Naitoh, Y Hori… - Cancer …, 2021 - Wiley Online Library
Peritoneal dissemination and malignant ascites in pancreatic ductal adenocarcinoma
(PDAC) patients represent a major clinical issue. Lysophosphatidic acid (LPA) is a lipid …
(PDAC) patients represent a major clinical issue. Lysophosphatidic acid (LPA) is a lipid …
[HTML][HTML] Intra-arterial infusion chemotherapy versus isolated upper abdominal perfusion for advanced pancreatic cancer: a retrospective cohort study on 454 patients
KR Aigner, S Gailhofer, E Selak, K Aigner - Journal of Cancer Research …, 2019 - Springer
Purpose The treatment of pancreatic carcinoma remains a challenge as prognosis is poor,
even if confined to a single anatomical region. A regional treatment of pancreatic cancer with …
even if confined to a single anatomical region. A regional treatment of pancreatic cancer with …
[HTML][HTML] Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity
P Bhoopathi, A Kumar, AK Pradhan, S Maji… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer without
effective therapies and with poor prognosis, causing 7% of all cancer-related fatalities in the …
effective therapies and with poor prognosis, causing 7% of all cancer-related fatalities in the …
[HTML][HTML] Cardiac atrophy, dysfunction, and metabolic impairments: a cancer-induced cardiomyopathy phenotype
LM Ogilvie, LJ Delfinis, B Coyle-Asbil, V Vudatha… - The American Journal of …, 2024 - Elsevier
Muscle atrophy and weakness are prevalent features of cancer. While extensive research
has characterized skeletal muscle wasting in cancer cachexia, limited studies have …
has characterized skeletal muscle wasting in cancer cachexia, limited studies have …